Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Prognostic Factors for Immune Thrombocytopenic Purpura Remission after Laparoscopic Splenectomy: A Cohort Study.

Kwiatkowska A, Radkowiak D, Wysocki M, Torbicz G, Gajewska N, Lasek A, Kulawik J, Budzyński A, Pędziwiatr M.

Medicina (Kaunas). 2019 Apr 18;55(4). pii: E112. doi: 10.3390/medicina55040112.

2.

Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.

Kwiatkowska A, Couture F, Ait-Mohand S, Desjardins R, Dory YL, Guérin B, Day R.

Sci Rep. 2019 Feb 14;9(1):2118. doi: 10.1038/s41598-018-37568-6.

3.

Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.

Dianati V, Navals P, Couture F, Desjardins R, Dame A, Kwiatkowska A, Day R, Dory YL.

J Med Chem. 2018 Dec 27;61(24):11250-11260. doi: 10.1021/acs.jmedchem.8b01381. Epub 2018 Dec 13.

PMID:
30501188
4.

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.

Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.

J Med Chem. 2018 Sep 27;61(18):8457-8467. doi: 10.1021/acs.jmedchem.8b01144. Epub 2018 Sep 17.

PMID:
30180568
5.

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.

Couture F, Sabbagh R, Kwiatkowska A, Desjardins R, Guay SP, Bouchard L, Day R.

Cancer Res. 2017 Dec 15;77(24):6863-6879. doi: 10.1158/0008-5472.CAN-17-1397. Epub 2017 Oct 9.

6.

Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.

Dianati V, Shamloo A, Kwiatkowska A, Desjardins R, Soldera A, Day R, Dory YL.

ChemMedChem. 2017 Aug 8;12(15):1169-1172. doi: 10.1002/cmdc.201700300. Epub 2017 Jul 19.

PMID:
28722823
7.

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.

Łepek T, Kwiatkowska A, Couture F, Ly K, Desjardins R, Dory Y, Prahl A, Day R.

Eur J Cell Biol. 2017 Aug;96(5):476-485. doi: 10.1016/j.ejcb.2017.04.001. Epub 2017 Apr 23.

PMID:
28483279
8.

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.

Panet F, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Day R.

Eur J Cell Biol. 2017 Aug;96(5):469-475. doi: 10.1016/j.ejcb.2017.03.006. Epub 2017 Mar 21.

PMID:
28347547
9.

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.

Małuch I, Levesque C, Kwiatkowska A, Couture F, Ly K, Desjardins R, Neugebauer WA, Prahl A, Day R.

J Med Chem. 2017 Apr 13;60(7):2732-2744. doi: 10.1021/acs.jmedchem.6b01499. Epub 2017 Mar 24.

PMID:
28287731
10.

Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.

Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R.

ChemMedChem. 2016 Feb 4;11(3):289-301. doi: 10.1002/cmdc.201500532. Epub 2016 Jan 11.

PMID:
26751825
11.

The efficacy of an education-based secondary outpatient prevention programme after acute coronary syndrome hospitalisations and treatment in Poland. The Patient Club initiative.

Siudak Z, Pers M, Dusza K, Franczak I, Zegzda A, Bechta M, Kwiatkowska A, Knutelska A, Zemla B, Kubiak A, Zarzycka M, Kudelko-Blacha N, Koźmińska P, Oleksy M, Dudek D.

Kardiol Pol. 2016;74(2):185-91. doi: 10.5603/KP.a2015.0225. Epub 2015 Nov 24.

12.

Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.

Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guérin B, Day R.

Biomed Res Int. 2015;2015:824014. doi: 10.1155/2015/824014. Epub 2015 May 31.

13.

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.

Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R.

Oncotarget. 2015 Feb 28;6(6):3680-93.

14.

Therapeutic uses of furin and its inhibitors: a patent review.

Couture F, Kwiatkowska A, Dory YL, Day R.

Expert Opin Ther Pat. 2015 Apr;25(4):379-96. doi: 10.1517/13543776.2014.1000303. Epub 2015 Jan 7. Review.

PMID:
25563687
15.

Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia.

Dietrich-Muszalska A, Kwiatkowska A.

Neuropsychiatr Dis Treat. 2014 May 5;10:703-9. doi: 10.2147/NDT.S60034. eCollection 2014.

16.

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R.

Transl Oncol. 2014 May 9. pii: S1936-5233(14)00043-6. doi: 10.1016/j.tranon.2014.04.008. [Epub ahead of print]

17.

Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.

Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):29-41. doi: 10.1021/jm400633d. Epub 2013 Dec 23.

PMID:
24359257
18.

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.

Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):98-109. doi: 10.1021/jm401457n. Epub 2013 Dec 18.

PMID:
24350995
19.

The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.

Dietrich-Muszalska A, Kopka J, Kwiatkowska A.

Neurochem Res. 2013 Jul;38(7):1490-5. doi: 10.1007/s11064-013-1050-z. Epub 2013 Apr 26.

PMID:
23619559
20.

Design, synthesis and structure-activity relationship of new arginine vasopressin analogues containing proline derivatives in position 2.

Kwiatkowska A, Lewandowska M, Borovičková L, Slaninová J, Lammek B, Prahl A.

Chem Biol Drug Des. 2013 Mar;81(3):420-8. doi: 10.1111/cbdd.12093.

PMID:
23205571
21.

The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.

Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R.

J Med Chem. 2012 Dec 13;55(23):10501-11. doi: 10.1021/jm3011178. Epub 2012 Nov 14.

22.

Micelle-bound conformations of neurohypophyseal hormone analogues modified with a Cα-disubstituted residue: NMR and molecular modelling studies.

Sikorska E, Kwiatkowska A.

J Biomol Struct Dyn. 2013;31(7):748-64. doi: 10.1080/07391102.2012.709459. Epub 2012 Aug 22.

PMID:
22908889
23.

Membrane structure and interactions of peptide hormones with model lipid bilayers.

Sikorska E, Iłowska E, Wyrzykowski D, Kwiatkowska A.

Biochim Biophys Acta. 2012 Dec;1818(12):2982-93. doi: 10.1016/j.bbamem.2012.07.008. Epub 2012 Jul 21.

24.

The effect of response style on self-reported Conscientiousness across 20 countries.

Mõttus R, Allik J, Realo A, Rossier J, Zecca G, Ah-Kion J, Amoussou-Yéyé D, Bäckström M, Barkauskiene R, Barry O, Bhowon U, Björklund F, Bochaver A, Bochaver K, de Bruin G, Cabrera HF, Chen SX, Church AT, Cissé DD, Dahourou D, Feng X, Guan Y, Hwang HS, Idris F, Katigbak MS, Kuppens P, Kwiatkowska A, Laurinavicius A, Mastor KA, Matsumoto D, Riemann R, Schug J, Simpson B, Tseung-Wong CN, Johnson W.

Pers Soc Psychol Bull. 2012 Nov;38(11):1423-36. doi: 10.1177/0146167212451275. Epub 2012 Jun 27.

25.

Conformational preferences of proline derivatives incorporated into vasopressin analogues: NMR and molecular modelling studies.

Sikorska E, Sobolewski D, Kwiatkowska A.

Chem Biol Drug Des. 2012 Apr;79(4):535-47. doi: 10.1111/j.1747-0285.2012.01318.x. Epub 2012 Feb 1.

PMID:
22226070
26.

Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists.

Kwiatkowska A, Ptach M, Borovičková L, Slaninová J, Lammek B, Prahl A.

Amino Acids. 2012 Aug;43(2):617-27. doi: 10.1007/s00726-011-1109-6. Epub 2011 Oct 29.

27.

NMR studies of new arginine vasopressin analogs modified with alpha-2-indanylglycine enantiomers at position 2 bound to sodium dodecyl sulfate micelles.

Lubecka E, Kwiatkowska A, Ciarkowski J, Sikorska E.

Biophys Chem. 2010 Oct;151(3):139-48. doi: 10.1016/j.bpc.2010.06.002. Epub 2010 Jun 16.

PMID:
20598431
28.

Influence of bulky 3,3'-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies.

Sikorska E, Kwiatkowska A, Sobolewski D, Slusarz R, Slusarz MJ.

Eur J Med Chem. 2010 Sep;45(9):4065-73. doi: 10.1016/j.ejmech.2010.05.066. Epub 2010 Jun 8.

PMID:
20580135
29.

New bradykinin B(2) receptor antagonists - influence of C-terminal segment modifications on their pharmacological properties.

Sleszyńska M, Kwiatkowska A, Sobolewski D, Wierzba TH, Katarzyńska J, Zabrocki J, Borovickova L, Slaninová J, Prahl A.

Acta Biochim Pol. 2009;56(4):641-8. Epub 2009 Dec 7.

30.

Novel analogues of arginine vasopressin containing alpha-2-indanylglycine enantiomers in position 2.

Kwiatkowska A, Sleszyńska M, Derdowska I, Prahl A, Sobolewski D, Borovicková L, Slaninová J, Lammek B.

J Pept Sci. 2010 Jan;16(1):15-20. doi: 10.1002/psc.1189.

PMID:
19924728
31.

Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.

Kwiatkowska A, Sobolewski D, Prahl A, Borovicková L, Slaninová J, Lammek B.

Eur J Med Chem. 2009 Jul;44(7):2862-67.

PMID:
19418631
32.

Analogues of AVP modified in the N-terminal part of the molecule with Pip isomers: TFA-catalysed peptide bond hydrolysis.

Sobolewski D, Prahl A, Kwiatkowska A, Slaninová J, Lammek B.

J Pept Sci. 2009 Mar;15(3):161-5. doi: 10.1002/psc.1094.

PMID:
19035576
33.

The effect of strip, tray and office peroxide bleaching systems on enamel surfaces in vitro.

Mielczarek A, Klukowska M, Ganowicz M, Kwiatkowska A, Kwaśny M.

Dent Mater. 2008 Nov;24(11):1495-500. doi: 10.1016/j.dental.2008.03.009. Epub 2008 Jun 24.

PMID:
18572238
34.

Trypsin inhibitors from the garden four o'clock (Mirabilis jalapa) and spinach (Spinacia oleracea) seeds: isolation, characterization and chemical synthesis.

Kowalska J, Pszczoła K, Wilimowska-Pelc A, Lorenc-Kubis I, Zuziak E, Ługowski M, Łegowska A, Kwiatkowska A, Sleszyńska M, Lesner A, Walewska A, Zabłotna E, Rolka K, Wilusz T.

Phytochemistry. 2007 Jun;68(11):1487-96. Epub 2007 May 3.

PMID:
17481678
35.

Influence of conformationally constrained amino acids replacing positions 2 and 3 of arginine vasopressin (AVP) and its analogues on their pharmacological properties.

Sobolewski D, Prahl A, Derdowska I, Kwiatkowska A, Slaninová J, Lammek B.

Protein Pept Lett. 2007;14(3):213-7.

PMID:
17346223
36.

Social representations of HIV/AIDS in five Central European and Eastern European countries: a multidimensional analysis.

Goodwin R, Kwiatkowska A, Realo A, Kozlova A, Nguyen Luu LA, Nizharadze G.

AIDS Care. 2004 Aug;16(6):669-80.

PMID:
15370056
37.

Clinical response of two brush-applied peroxide whitening systems.

Barlow A, Gerlach RW, Date RF, Brennan K, Struzycka I, Kwiatkowska A, Wierzbicka M.

J Clin Dent. 2003;14(3):59-63.

PMID:
14520775
38.

Social representations of HIV/AIDS in Central and Eastern Europe.

Goodwin R, Kozlova A, Kwiatkowska A, Anh Nguyen Luu L, Nizharadze G, Realo A, Külvet A, Rämmer A.

Soc Sci Med. 2003 Apr;56(7):1373-84.

PMID:
12614690
39.

Values and sexual behaviour in central and eastern europe.

Goodwin R, Realo A, Kwiatkowska A, Kozlova A, Luu LA, Nizharadze G.

J Health Psychol. 2002 Jan;7(1):45-56. doi: 10.1177/1359105302007001651.

PMID:
22114226

Supplemental Content

Loading ...
Support Center